Business · 30/04/2026Updated: 10/16/2026 · 1 min read
ChemoCentryx, Inc. Faces FDA Proposal to Withdraw Approval of Avacopan Capsule
Summary
The FDA is proposing to withdraw approval of ChemoCentryx, Inc.'s new drug application for TAVNEOS (avacopan) capsule, 10 milligrams, citing a lack of substantial evidence and untrue statements of material fact.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →